ClinicalTrials.gg
Not yet recruitingNCT06885021Updated Mar 19, 2025

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

A Phase 3 interventional study of HDM1002 200mg, oral, once daily, 52 weeks and HDM1002 400mg, oral, once daily, 52 weeks in Overweight and Obesity, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
780
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Obesity by Huadong Medicine Co., Ltd. — 10 open to participants now, 11 under way, 5 of them phase 3. Obesity · Huadong Medicine Co., Ltd..

Planned enrollment
2nd of 13
780 · median 200
Started
2025
with 3 others
Phase 3
5 of 13
5 open now
Primary completion
2026-05
later than 3 of 10 live
Registered
5th of 13
by date

Among the 13 studies in Obesity by Huadong Medicine Co., Ltd., this one is the 2nd largest by planned enrollment, is one of 4 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 3 of the 10 other live ones, and was the 5th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

10 of the 13 studies in Obesity by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Obesity by Huadong Medicine Co., Ltd., or all of them as a file.
02

Study summary

A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

03

Conditions studied

  • Overweight and Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 780 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥28 but \< 40.0 kg/m2 at screening or randomization,or BMI≥24.0 kg/m2 but \< 28 kg/m2 with any of the following:

    1. Hypertension
    2. Dyslipidemia
    3. Obstructive sleep apnea syndrome
    4. MASH
    5. Pain in the weight-bearing joints
  • At least one previous failure to lose weight through lifestyle modification was defined as \< 5% weight loss after ≥3 months of lifestyle modification

Exclusion criteria

Exclusion Criteria:

  • Weight change ≥5% as reported or documented.
  • Previous diagnosis of type 1, type 2, or any other type of diabetes.
  • Diagnosis of overweight or obesity due to other diseases or medications.
  • History or family history of medullary thyroid carcinoma, C cell hyperplasia, or multiple endocrine neoplasia type 2.
  • Have diseases or conditions that affect gastric emptying or gastrointestinal absorption of nutrients, such as bariatric surgery or other gastrectomy, irritable bowel syndrome, dyspepsia, chronic pancreatitis, etc. Or a history of acute pancreatitis or acute gallbladder disease within 3 months before signing ICF.
  • GLP-1R agonist use within 6 months prior to signing ICF.
  • Use of hypoglycemic drugs within 3 months before signing ICF.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
780 participants (estimated)

Study arms

  • Experimental
    HDM1002 tablets 200mg once daily

    HDM1002 200mg, oral, once daily, 52weeks

    Drug: HDM1002 200mg, oral, once daily, 52 weeks

  • Experimental
    HDM1002 tablets 400mg once daily

    HDM1002 400mg, oral, once daily, 52weeks

    Drug: HDM1002 400mg, oral, once daily, 52 weeks

  • Placebo comparator
    Placebo

    HDM1002 placebo, oral, once daily, 52weeks

    Drug: HDM1002 placebo, oral, once daily, 52 weeks

Interventions

07

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Body Weight

    Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg,

    Time frame: 44weeks

  2. Percentage Change of Participants Achieving Weight Loss ≥ 5%

    Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg

    Time frame: 44weeks

Secondary outcomes

  1. Percentage Change of Participants Achieving Weight Loss ≥ 10% and ≥ 15%

    Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: 44weeks

  2. Change From Baseline in Waist Circumference

    Waist Circumference was recorded in cm

    Time frame: 44 weeks, 52 weeks

  3. Percentage Change of Participants Achieving Weight Loss ≥ 5% , ≥ 10% and ≥ 15%

    Weight was recorded in kilograms (kg), and accuracy to the nearest 0.1 kg.

    Time frame: 52 weeks

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for May 2026, 14 months later.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 14 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Mar 19, 2025
StartEst.
Mar 28, 2025
Primary completionEst.
May 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06885021
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Mar 28, 2025 (estimated)
Primary completion
May 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Mar 19, 2025

Study contacts

Jing Liu Jing Liu
Contact
cxyliujing@eastchinapharm.com
+8657189903388
Wenwen Tu
Contact
tuwenwen@eastchinapharm.com
+86-0571-89903388

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HDM1002

Start the discussion